Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Molecular Mechanism of Congenital Heart Disease and Pulmonary Hypertension

Directory of Open access Books (OAPEN Foundation)(2020)10.1007/978-981-15-1185-1Source: DataRank Database

Molecular Mechanism of Congenital Heart Disease and Pulmonary Hypertension is a research paper published in Directory of Open access Books (OAPEN Foundation) (2020). On theSindex it has a DataRank of 0.905. It has been cited 21 times, with 20 citing works in its 1-hop citation network.

N/A

0.905DataRank · unranked

Scored on demand from live citation data

Open Access21 citations · 20 citing works in its network

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Impact (FWCI 8.41)OA: goldTopics (15)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 51%Citation Network 49%

Base Score Contribution

0.464

From this paper's citation signal

Citation Network Contribution

0.441

From 19 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 20 citers.

Practical considerations in the management of inhaled prostacyclin therapy for pulmonary hypertension associated with interstitial lung disease (WHO group 3)
Respiratory Medicine20227 citations26 referencesContributes 0.080
Safety and pharmacokinetics of ralinepag, a novel oral prostacyclin receptor agonist
JHLT Open20254 citations26 referencesContributes 0.062
Diesel exhaust particles distort lung epithelial progenitors and their fibroblast niche
Environmental Pollution202239 citations68 referencesContributes 0.054
Prostacyclin Released by Cancer-Associated Fibroblasts Promotes Immunosuppressive and Pro-Metastatic Macrophage Polarization in the Ovarian Cancer Microenvironment
Cancers202226 citations72 referencesContributes 0.046
Discovery and Characterization of VU0542270, the First Selective Inhibitor of Vascular Kir6.1/SUR2B KATP Channels
Molecular Pharmacology20249 citations58 referencesContributes 0.040

Authors (4)

H. Scott Baldwin ORCID,Jeffrey R. Fineman,Hiroyuki Yamagishi ORCID,Toshio Nakanishi ORCID

Live enrichment

PubMed:19965766 OpenAlex:https://openalex.org/W3123797270

FWCI

8.41

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

goldLicense: cc-by

https://link.springer.com/content/pdf/10.1007/978-981-15-1185-1.pdf?pdf=button

GREENhttps://library.oapen.org/bitstream/20.500.12657/39568/1/2020_Book_MolecularMechanismOfCongenital.pdf

https://link.springer.com/content/pdf/10.1007/978-981-15-1185-1.pdf?pdf=button

publisherhttps://link.springer.com/content/pdf/10.1007/978-981-15-1185-1.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/978-981-15-1185-1

Fields of Study

Pulmonary Hypertension Research and TreatmentsMedicineBiology

Keywords

Ductus arteriosusMechanism (biology)Pulmonary hypertensionMorphogenesisHeart diseaseCardiologyMedicineTranscription factorInternal medicineBiologyGeneGenetics

Sustainable Development Goals

SDG 0: Good health and well-being

Related Papers (1)

Vascular K ATP channel structural dynamics reveal regulatory mechanism by Mg-nucleotides

N/A

1.4DataRank · unranked

Proceedings of the National Academy of Sciences(2021)

co-cited

10.1073/pnas.2109441118